Relationship of circulating c5a and complement factor h levels with disease control in pregnant women with asthma

Anikó Bohács, András Bikov, István Ivancsó, Ibolya Czaller, Renáta Böcskei, V. Müller, J. Rigó, G. Losonczy, L. Tamási

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Asthma often complicates pregnancy and represents a risk of serious pregnancy complications. The complement system contributes to asthma pathogenesis and is up-regulated in healthy gestation as well. The anaphylatoxin C5a has a major pro-inflammatory role, and the complement factor H is a main soluble regulator protein both in asthma and during pregnancy; however, peripheral levels of these complement factors and their relationship to disease control have not yet been evaluated in pregnant subjects with asthma. METHODS: The present study aimed to investigate circulating C5a and complement factor H levels in asthma (non-pregnant subjects with asthma; n = 19) and in pregnancy with asthma (pregnant subjects with asthma; n = 22), compared with healthy non-pregnant (n = 21) and healthy pregnant women (n = 13) and to test their relationship to clinical parameters of asthma (lung function, airway inflammation, and symptoms). RESULTS: Circulating C5a levels were higher in the pregnant asthma subject group compared with the healthy non-pregnant, healthy pregnant, and non-pregnant asthma groups: median 2.629 (interquartile range [IQR] 2.257–3.052) ng/mL versus 1.84 (IQR 1.576 –2.563), 1.783 (IQR 0.6064 –2.786), and 2.024 (IQR 1.232–2.615) ng/mL, respectively (P =. 02 in all cases). C5a correlated negatively with FEV1 (r = -0.44, P =. 039) and FVC values (r = -0.64, P =. 001) in the pregnant asthma group and positively with fraction of exhaled nitric oxide levels in the nonpregnant asthma group (n = 12, r - 0.78, P =. 004). Complement factor H levels were elevated in both the healthy pregnant and pregnant asthma subject groups compared with the healthy non-pregnant group (median 1,082 [IQR 734.9–1,224] and 910.7 [IQR 614.5–1076] µg/mL vs 559.7 [IQR 388.7– 783.1]µg/mL, P=.002 and P=.004, respectively) but not in the pregnant asthma group compared with the non-pregnant asthma group (median 687.4 [IQR 441.6–947.6] µg/mL, P =. 10). CONCLUSIONS: Asthma during pregnancy increases the circulating level of pro-inflammatory C5a, which is accompanied by impaired lung function and partly counteracted by the gestation-specific elevation of regulatory complement factor H level (detected in pregnancy both in healthy and subjects with asthma).

Original languageEnglish
Pages (from-to)502-509
Number of pages8
JournalRespiratory Care
Volume61
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Complement C5a
Pregnant Women
Asthma
Complement Factor H
Pregnancy
Anaphylatoxins

Keywords

  • Asthma
  • Biomarker
  • C5a
  • Complement
  • Complement factor H
  • Pregnancy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Relationship of circulating c5a and complement factor h levels with disease control in pregnant women with asthma. / Bohács, Anikó; Bikov, András; Ivancsó, István; Czaller, Ibolya; Böcskei, Renáta; Müller, V.; Rigó, J.; Losonczy, G.; Tamási, L.

In: Respiratory Care, Vol. 61, No. 4, 01.04.2016, p. 502-509.

Research output: Contribution to journalArticle

Bohács, Anikó ; Bikov, András ; Ivancsó, István ; Czaller, Ibolya ; Böcskei, Renáta ; Müller, V. ; Rigó, J. ; Losonczy, G. ; Tamási, L. / Relationship of circulating c5a and complement factor h levels with disease control in pregnant women with asthma. In: Respiratory Care. 2016 ; Vol. 61, No. 4. pp. 502-509.
@article{4de207cd3d204243bfb9f3abf4f90c7b,
title = "Relationship of circulating c5a and complement factor h levels with disease control in pregnant women with asthma",
abstract = "BACKGROUND: Asthma often complicates pregnancy and represents a risk of serious pregnancy complications. The complement system contributes to asthma pathogenesis and is up-regulated in healthy gestation as well. The anaphylatoxin C5a has a major pro-inflammatory role, and the complement factor H is a main soluble regulator protein both in asthma and during pregnancy; however, peripheral levels of these complement factors and their relationship to disease control have not yet been evaluated in pregnant subjects with asthma. METHODS: The present study aimed to investigate circulating C5a and complement factor H levels in asthma (non-pregnant subjects with asthma; n = 19) and in pregnancy with asthma (pregnant subjects with asthma; n = 22), compared with healthy non-pregnant (n = 21) and healthy pregnant women (n = 13) and to test their relationship to clinical parameters of asthma (lung function, airway inflammation, and symptoms). RESULTS: Circulating C5a levels were higher in the pregnant asthma subject group compared with the healthy non-pregnant, healthy pregnant, and non-pregnant asthma groups: median 2.629 (interquartile range [IQR] 2.257–3.052) ng/mL versus 1.84 (IQR 1.576 –2.563), 1.783 (IQR 0.6064 –2.786), and 2.024 (IQR 1.232–2.615) ng/mL, respectively (P =. 02 in all cases). C5a correlated negatively with FEV1 (r = -0.44, P =. 039) and FVC values (r = -0.64, P =. 001) in the pregnant asthma group and positively with fraction of exhaled nitric oxide levels in the nonpregnant asthma group (n = 12, r - 0.78, P =. 004). Complement factor H levels were elevated in both the healthy pregnant and pregnant asthma subject groups compared with the healthy non-pregnant group (median 1,082 [IQR 734.9–1,224] and 910.7 [IQR 614.5–1076] µg/mL vs 559.7 [IQR 388.7– 783.1]µg/mL, P=.002 and P=.004, respectively) but not in the pregnant asthma group compared with the non-pregnant asthma group (median 687.4 [IQR 441.6–947.6] µg/mL, P =. 10). CONCLUSIONS: Asthma during pregnancy increases the circulating level of pro-inflammatory C5a, which is accompanied by impaired lung function and partly counteracted by the gestation-specific elevation of regulatory complement factor H level (detected in pregnancy both in healthy and subjects with asthma).",
keywords = "Asthma, Biomarker, C5a, Complement, Complement factor H, Pregnancy",
author = "Anik{\'o} Boh{\'a}cs and Andr{\'a}s Bikov and Istv{\'a}n Ivancs{\'o} and Ibolya Czaller and Ren{\'a}ta B{\"o}cskei and V. M{\"u}ller and J. Rig{\'o} and G. Losonczy and L. Tam{\'a}si",
year = "2016",
month = "4",
day = "1",
doi = "10.4187/respcare.04339",
language = "English",
volume = "61",
pages = "502--509",
journal = "Respiratory Care",
issn = "0020-1324",
publisher = "Daedalus Enterprises Inc.",
number = "4",

}

TY - JOUR

T1 - Relationship of circulating c5a and complement factor h levels with disease control in pregnant women with asthma

AU - Bohács, Anikó

AU - Bikov, András

AU - Ivancsó, István

AU - Czaller, Ibolya

AU - Böcskei, Renáta

AU - Müller, V.

AU - Rigó, J.

AU - Losonczy, G.

AU - Tamási, L.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - BACKGROUND: Asthma often complicates pregnancy and represents a risk of serious pregnancy complications. The complement system contributes to asthma pathogenesis and is up-regulated in healthy gestation as well. The anaphylatoxin C5a has a major pro-inflammatory role, and the complement factor H is a main soluble regulator protein both in asthma and during pregnancy; however, peripheral levels of these complement factors and their relationship to disease control have not yet been evaluated in pregnant subjects with asthma. METHODS: The present study aimed to investigate circulating C5a and complement factor H levels in asthma (non-pregnant subjects with asthma; n = 19) and in pregnancy with asthma (pregnant subjects with asthma; n = 22), compared with healthy non-pregnant (n = 21) and healthy pregnant women (n = 13) and to test their relationship to clinical parameters of asthma (lung function, airway inflammation, and symptoms). RESULTS: Circulating C5a levels were higher in the pregnant asthma subject group compared with the healthy non-pregnant, healthy pregnant, and non-pregnant asthma groups: median 2.629 (interquartile range [IQR] 2.257–3.052) ng/mL versus 1.84 (IQR 1.576 –2.563), 1.783 (IQR 0.6064 –2.786), and 2.024 (IQR 1.232–2.615) ng/mL, respectively (P =. 02 in all cases). C5a correlated negatively with FEV1 (r = -0.44, P =. 039) and FVC values (r = -0.64, P =. 001) in the pregnant asthma group and positively with fraction of exhaled nitric oxide levels in the nonpregnant asthma group (n = 12, r - 0.78, P =. 004). Complement factor H levels were elevated in both the healthy pregnant and pregnant asthma subject groups compared with the healthy non-pregnant group (median 1,082 [IQR 734.9–1,224] and 910.7 [IQR 614.5–1076] µg/mL vs 559.7 [IQR 388.7– 783.1]µg/mL, P=.002 and P=.004, respectively) but not in the pregnant asthma group compared with the non-pregnant asthma group (median 687.4 [IQR 441.6–947.6] µg/mL, P =. 10). CONCLUSIONS: Asthma during pregnancy increases the circulating level of pro-inflammatory C5a, which is accompanied by impaired lung function and partly counteracted by the gestation-specific elevation of regulatory complement factor H level (detected in pregnancy both in healthy and subjects with asthma).

AB - BACKGROUND: Asthma often complicates pregnancy and represents a risk of serious pregnancy complications. The complement system contributes to asthma pathogenesis and is up-regulated in healthy gestation as well. The anaphylatoxin C5a has a major pro-inflammatory role, and the complement factor H is a main soluble regulator protein both in asthma and during pregnancy; however, peripheral levels of these complement factors and their relationship to disease control have not yet been evaluated in pregnant subjects with asthma. METHODS: The present study aimed to investigate circulating C5a and complement factor H levels in asthma (non-pregnant subjects with asthma; n = 19) and in pregnancy with asthma (pregnant subjects with asthma; n = 22), compared with healthy non-pregnant (n = 21) and healthy pregnant women (n = 13) and to test their relationship to clinical parameters of asthma (lung function, airway inflammation, and symptoms). RESULTS: Circulating C5a levels were higher in the pregnant asthma subject group compared with the healthy non-pregnant, healthy pregnant, and non-pregnant asthma groups: median 2.629 (interquartile range [IQR] 2.257–3.052) ng/mL versus 1.84 (IQR 1.576 –2.563), 1.783 (IQR 0.6064 –2.786), and 2.024 (IQR 1.232–2.615) ng/mL, respectively (P =. 02 in all cases). C5a correlated negatively with FEV1 (r = -0.44, P =. 039) and FVC values (r = -0.64, P =. 001) in the pregnant asthma group and positively with fraction of exhaled nitric oxide levels in the nonpregnant asthma group (n = 12, r - 0.78, P =. 004). Complement factor H levels were elevated in both the healthy pregnant and pregnant asthma subject groups compared with the healthy non-pregnant group (median 1,082 [IQR 734.9–1,224] and 910.7 [IQR 614.5–1076] µg/mL vs 559.7 [IQR 388.7– 783.1]µg/mL, P=.002 and P=.004, respectively) but not in the pregnant asthma group compared with the non-pregnant asthma group (median 687.4 [IQR 441.6–947.6] µg/mL, P =. 10). CONCLUSIONS: Asthma during pregnancy increases the circulating level of pro-inflammatory C5a, which is accompanied by impaired lung function and partly counteracted by the gestation-specific elevation of regulatory complement factor H level (detected in pregnancy both in healthy and subjects with asthma).

KW - Asthma

KW - Biomarker

KW - C5a

KW - Complement

KW - Complement factor H

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84961704500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961704500&partnerID=8YFLogxK

U2 - 10.4187/respcare.04339

DO - 10.4187/respcare.04339

M3 - Article

VL - 61

SP - 502

EP - 509

JO - Respiratory Care

JF - Respiratory Care

SN - 0020-1324

IS - 4

ER -